A systematic review and meta-analysis presented at ACR Convergence 2022 provide insight into the effects of belimumab in patient populations with cutaneous lupus erythematosus, with or without ...

To improve cutaneous lupus erythematosus (CLE) clinical study design, investigators analyzed a range of Cutaneous Lupus Activity and Severity Index (CLASI) outcomes in a group of 140 people to ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio PHILADELPHIA — Belimumab demonstrated a ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Treatment with ...

ICP-488 is an oral, potent, and selective TYK2 allosteric inhibitor. By binding to the JH2 domain, ICP-488 blocks the signal transduction of IL-23, IL-12, type 1 IFN, and other inflammatory cytokines, ...

Lupus erythematosus is a heterogeneous autoimmune disorder that frequently manifests with distinctive cutaneous involvement. The cutaneous lesions, which range from a malar rash to more indurated, ...

Please provide your email address to receive an email when new articles are posted on . Researchers found that long-term remission of cutaneous lupus erythematosus occurred in nearly 20% of patients, ...

In a new letter, published in the Journal of the European Academy of Dermatology and Venereology, members of the lupus community underscore the critical need to recognize the unique challenges of ...

Hypertrophic LE is a rare subset of chronic cutaneous LE and represents 2% of the total chronic cutaneous lesions of LE. [1,2] Hypertrophic LE is similar to discoid LE but with marked hyperkeratosis ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Maureen A. McMahon ...

RECENT work from this laboratory indicates that patients who have rejected skin homografts manifest a "delayed" type of hypersensitivity to homologous leukocytes. This is evidenced by typical erythema ...